Verifying in vitro‐determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically‐based pharmacokinetic modeling

Cannabidiol (CBD) is approved for treatment of seizures associated with two forms of epilepsy that become apparent in infancy or early childhood. To consider an adult physiologically‐based pharmacokinetic (PBPK) model for pediatric scaling, we assessed in vitro‐derived cytochrome P450 (CYP) and urid...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeung, Cindy H. T., Beers, Jessica L., Jackson, Klarissa D., Edginton, Andrea N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014054/
https://www.ncbi.nlm.nih.gov/pubmed/36540909
http://dx.doi.org/10.1002/psp4.12908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014054/
https://www.ncbi.nlm.nih.gov/pubmed/36540909
http://dx.doi.org/10.1002/psp4.12908

Ejemplares similares